(NASDAQ: ACLX) Arcellx's forecast annual revenue growth rate of 4.24% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Arcellx's revenue in 2024 is $110,319,000.On average, 5 Wall Street analysts forecast ACLX's revenue for 2024 to be $6,409,773,408, with the lowest ACLX revenue forecast at $3,801,356,496, and the highest ACLX revenue forecast at $10,739,571,254. On average, 5 Wall Street analysts forecast ACLX's revenue for 2025 to be $5,987,928,430, with the lowest ACLX revenue forecast at $3,801,356,496, and the highest ACLX revenue forecast at $7,722,350,128.
In 2026, ACLX is forecast to generate $6,855,324,068 in revenue, with the lowest revenue forecast at $4,709,458,326 and the highest revenue forecast at $10,664,916,836.